Table 2.
Composite End-Stage Liver Disease Models Variables
| Baseline | Baseline + Amino Acids | Baseline + Bile Acids | Baseline + Fatty Acids | Baseline + Lipids | Baseline + Oxylipins | Baseline + All Metabolites |
|---|---|---|---|---|---|---|
| (AUC = 0.79) | (AUC = 0.84) | (AUC = 0.82) | (AUC = 0.78) | (AUC = 0.85) | (AUC = 0.79) | (AUC = 0.89) |
| INR | INR | INR | INR | ALBUMIN | INR | CREAT |
| ALBUMIN | CREAT | ALBUMIN | ALBUMIN | CREAT | ALBUMIN | DCA |
| CREAT | FIB-4 | CREAT | CREAT | FIB-4 | CREAT | TCDCA |
| CD4 | Arg | CD4 | CD4 | AC(3:0) | FIB-4 | 12S-HHTrE |
| FIB-4 | His | FIB-4 | FIB-4 | AC(14:2-OH) | 12S-HHTrE | AC(3:0) |
| Phe | CDCA | FA 16:1 (palmitoleic) | LPC(15:0) | 5(S)-HEPE | LPC(17:0) | |
| Val | DCA | FA 20:4 omega-6 (AA) | LPC(17:0) | 14-HDoHE | LPC-O(16:1) | |
| Met-SO | TCDCA | FA 22:5 omega-6 (Osbond) | LPC(20:4) | PC(42:7) | ||
| TUDCA | LPC-O(16:1) | PC-O(36:1) | ||||
| PC(32:0) | PC-O(40:8) | |||||
| PC(42:7) | SM(35:1) | |||||
| PC-O(36:1) | DG(39:0) | |||||
| PC-O(40:8) | His | |||||
| SM(35:1) | Val | |||||
| SM(36:2) | Met-SO | |||||
| CE(22:5) | SDMA | |||||
| DG(39:0) |
Abbreviations: AC, acylcarnitine; AUC, area under curve; CDCA, chenodesoxycholic acid; CE, cholesteryl ester; CREAT, creatinine; DCA, deoxycholic acid; DG, diacylglycerol; FA, fatty acid; LPC, lysophosphatidylcholine; HDoHE, hydroxy-docosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HHTrE, hydroxyheptadecatrenoic acid; INR, international normalized ratio; Met-SO, methionine sulfoxide; PC, phosphatidylcholine; SDMA, symmetric dimethylarginine; SM, sphingomyelin; TCDCA, taurochenodeoxycholic acid.